Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > routes: IV

& legal

: Currently legal in most jurisdictions with thujone limits

or [[USLegal:Prescription only|Rx-only]] in US

Use the filters below to narrow your results.

Acyclovir (1) · Allopurinol (1) · Azithromycin (1) · Bumetanide (1) · Calcitriol (1,25-dihydroxyvitamin D3) (1) · Cefuroxime (axetil oral, sodium IV) (1) · Dexamethasone (1) · Diltiazem (1) · Doxycycline (1) · Enalapril (and enalaprilat IV) (1) · Epinephrine (adrenaline) (1) · Fluconazole (1) · Fluorouracil (5-FU) (1) · Furosemide (1) · Hydralazine (1) · Insulin aspart (1) · Ketorolac (tromethamine) (1) · Lactated Ringer's solution (1) · Levothyroxine (1) · Liothyronine (T3, triiodothyronine sodium) (1) · Methotrexate (1) · Methylprednisolone (1) · Metronidazole (1) · Nitroglycerin (glyceryl trinitrate, GTN) (1) · Ondansetron (1) · Pantoprazole (1) · Tobramycin (1) · Torsemide (1) · Verapamil (1)

Apresoline (historical); mostly generic; combination with isosorbide dinitrate marketed as BiDil for self-identified Black patients with HFrEF (1) · Bumex (1) · Calan, Calan SR, Verelan, Verelan PM, Isoptin SR (1) · Cardizem, Tiazac, Cartia XT, Dilacor XR, Taztia XT, Matzim LA (1) · Ceftin (oral), Zinacef (IV) (1) · Cytomel (oral), Triostat (IV) (1) · Decadron (historical), Dexpak (taper pack), Hemady, Ozurdex (intravitreal) (1) · Demadex, Soaanz (1) · Diflucan (1) · Efudex (topical), Carac (topical), Fluoroplex (topical); generic IV (1) · EpiPen, EpiPen Jr, Auvi-Q, Adrenaclick, Symjepi; many generic (1) · Flagyl, Metrocream, Metrogel, Metrogel-Vaginal, Noritate (1) · Lactated Ringer's Injection (Baxter, B. Braun, ICU Medical); Hartmann's solution (intl.) (1) · Lasix (1) · Medrol (oral), Solu-Medrol (IV/IM), Depo-Medrol (depot injection) (1) · Nitrostat, Nitrolingual, NitroMist, Nitro-Bid, Nitro-Dur, Minitran, Rectiv (1) · NovoLog, Fiasp (ultra-rapid), Trurapi (1) · Protonix (1) · Rocaltrol (oral), Calcijex (IV); topical Vectical for psoriasis (1) · Synthroid, Levoxyl, Tirosint, Unithroid, Euthyrox (1) · Tobrex (ophthalmic), Tobi, Tobi Podhaler, Bethkis (inhaled, cystic fibrosis), generic IV (1) · Toradol (IV/IM, US brand discontinued), Sprix (nasal spray), Acular and Acuvail (ophthalmic) (1) · Trexall, Otrexup, Rasuvo, Xatmep, Rheumatrex (discontinued) (1) · Vasotec, Vasotec IV, Epaned (1) · Vibramycin, Doryx, Oracea, Adoxa, Monodox, Acticlate (1) · Zithromax, Z-Pak, Zmax (1) · Zofran, Zofran ODT (1) · Zovirax (1) · Zyloprim, Aloprim (IV) (1)

[[:Category:Antihypertensives|Antihypertensive]] (4) · [[:Category:Antianginals|Antianginal]] (3) · [[:Category:Immunosuppressants|Immunosuppressant]] (3) · [[:Category:Loop_diuretics|Loop diuretic]] (3) · [[:Category:Antiarrhythmics|Antiarrhythmic (class IV)]] (2) · [[:Category:Antineoplastics|Antineoplastic]] (2) · [[:Category:Calcium_channel_blockers|Calcium channel blocker (non-dihydropyridine)]] (2) · [[:Category:Corticosteroids|Corticosteroid]] (2) · [[:Category:Hormone_replacement|Hormone replacement]] (2) · [[:Category:Thyroid_hormones|Thyroid hormone]] (2)

Other values:

None (22) · Synthetic T4 (thyroxine); peripherally deiodinated to T3 (triiodothyronine), the active hormone. '"`UNIQ--vote-00000031-QINU`"' Narrow therapeutic index; brand-to-generic switches can shift TSH and require re-titration'"`UNIQ--ref-00000032-QINU`"'. (1) · '"`UNIQ--vote-00000086-QINU`"' Calcium content is a relative contraindication for co-administration with citrated blood products through the same line'"`UNIQ--ref-00000087-QINU`"'. (1) · '"`UNIQ--vote-00000117-QINU`"' Compared with omeprazole, pantoprazole has a more linear pharmacokinetic profile and is metabolized predominantly via CYP2C19 with CYP3A4 contribution; less CYP2C19-driven drug interaction with clopidogrel than omeprazole'"`UNIQ--ref-00000118-QINU`"'. (1) · '"`UNIQ--vote-0000063C-QINU`"' Avoid in HFrEF (negative inotropy). CYP3A4 substrate AND moderate inhibitor — interacts substantially with statins (especially simvastatin), tacrolimus, cyclosporine, and many other CYP3A4 substrates'"`UNIQ--ref-0000063D-QINU`"'. (1) · '"`UNIQ--vote-00000860-QINU`"' Activates the glucocorticoid receptor to broadly remodel inflammatory, immune, and metabolic transcription. Unlike prednisone, it does not require hepatic activation, making it the preferred oral choice in severe hepatic dysfunction'"`UNIQ--ref-00000861-QINU`"'. (1) · '"`UNIQ--vote-00000B40-QINU`"' The TRANSFORM-HF trial (2023) found no all-cause mortality difference between torsemide and furosemide in heart failure, although torsemide remains pharmacologically preferred where furosemide oral absorption is unreliable'"`UNIQ--ref-00000B41-QINU`"'. (1) · '"`UNIQ--vote-00000E4A-QINU`"' The narrow safe-bolus window for IV use (sharp risk of arrhythmia, hypertensive emergency, intracerebral hemorrhage) is why anaphylaxis dosing is '''IM, not IV''', outside critical care'"`UNIQ--ref-00000E4B-QINU`"'. (1)

0.5-1 mg PO/IV once or twice daily; titrate to clinical response. Approximate equipotency: bumetanide 1 mg ≈ furosemide 40 mg ≈ torsemide 20 mg (1) · 1.6 mcg/kg/d in young healthy adults; 25-50 mcg/d in elderly or cardiac disease, titrated by TSH at 6-8 weeks (1) · 10-20 mg PO/IV once daily; titrate by clinical response. 1:1 IV to PO conversion (unlike furosemide's 1:2) (1) · 100 mg PO BID; rickettsial 200 mg/d; doxy-PEP 200 mg within 72 hours after condomless sex (1) · 100 mg PO once daily; titrate by 100 mg every 2-4 weeks to a serum urate target (typically <6 mg/dL, or <5 in tophaceous disease) (1) · 20-40 mg PO/IV; titrate by clinical response. In diuretic-resistant heart failure or CKD, doses to 200 mg or higher may be needed (1) · 250-500 mg PO BID × 7-14 days; IV 1.5 g q8h for serious infections (1) · 4-8 mg PO or IV every 8 hours as needed; 16 mg single dose preoperatively for PONV prevention (1) · 40 mg PO or IV once daily (1) · 5-10 mg PO once daily (2.5 mg if on diuretic or in heart failure); titrate to 10-20 mg BID for HFrEF (1) · 500 mg PO day 1, then 250 mg PO daily days 2-5 (Z-Pak); 1 g PO single dose for chlamydia; pediatric dosing 10 mg/kg day 1, 5 mg/kg days 2-5 (1) · 500 mg PO TID × 7-10 days (most indications); 2 g single dose for trichomoniasis; 500 mg IV q8h for severe anaerobic infection; rectal 1 g BID (1) · Anaphylaxis IM 0.3-0.5 mg (adult) into lateral thigh, repeat q5-15 minutes prn; pediatric 0.01 mg/kg IM (max 0.3 mg, max 0.5 mg in adolescents); cardiac arrest 1 mg IV/IO q3-5 minutes; severe asthma neb 0.1 mg/kg up to 5 mg; never IV bolus for anaphylaxis outside critical care (1) · ER 180-240 mg PO once daily; IR 30 mg PO QID; IV 0.25 mg/kg over 2 min for acute rate control, then 5-15 mg/h infusion (1) · Hypothyroidism: 5-25 mcg PO daily (start low, titrate slowly); myxedema coma: 5-20 mcg IV q4-12h with T4 loading (1) · IM: 60 mg single dose or 30 mg every 6 hours. IV: 30 mg every 6 hours. Oral (continuation only): 10-20 mg every 4-6 hours. Sprix nasal: 31.5 mg every 6-8 hours. '''Maximum 5 days total combined use''' (1) · Indication-specific: 0.5-9 mg PO/IV daily for inflammation; 4 mg IV q6h for cerebral edema; 40 mg PO once weekly in MM; 6 mg PO/IV daily ×10 days for severe COVID-19; 0.6 mg/kg PO single dose for croup (max 16 mg) (1) · Initial genital herpes 400 mg PO TID × 7-10 days; episodic 800 mg TID × 2 days; suppression 400 mg BID; herpes zoster 800 mg 5×/day × 7 days; HSV encephalitis 10 mg/kg IV q8h × 14-21 days (1) · IR 80-120 mg PO TID; ER 180-240 mg PO daily; IV 2.5-5 mg over 2 min for SVT termination (under monitoring); cluster prophylaxis up to 480-960 mg/d in divided doses (1) · IV: traditional 1-1.7 mg/kg q8h or extended-interval 5-7 mg/kg q24h with target-trough monitoring; inhaled CF 300 mg BID × 28 days on / 28 days off; ophthalmic 1-2 drops in affected eye(s) q4h (1) · Oral 0.25 mcg daily, titrate by serum calcium and PTH; IV in CKD 0.5-3 mcg three times weekly (1) · PO 10 mg QID; IV 5-10 mg every 20-30 minutes for hypertensive emergency (1) · PO Medrol Dosepak (5-day taper from 24 mg to 4 mg) is the prototypic short-course outpatient regimen; IV pulse 1 g daily for 3-5 days for MS relapse; intra-articular 4-80 mg per joint q1-5 weeks (1) · Rheumatologic: 7.5-15 mg PO or SC '''once weekly''' (not daily — daily dosing is a recognized fatal error); folic acid 1 mg PO daily on non-MTX days; oncology dosing is far higher and indication-specific (1) · SC 4-6 units (or 1 unit per 10-15 g carbs) at meals; titrate to postprandial glucose (1) · SL 0.3-0.6 mg every 5 minutes up to 3 doses for acute angina (call EMS if not resolved after the third); IV infusion 5-10 mcg/min titrated; transdermal patch 0.2-0.4 mg/hr for 12-14 hours daily (nitrate-free interval prevents tolerance) (1) · Topical: 0.5-5% cream/solution to lesions BID × 2-4 weeks; systemic IV: regimen-specific in cancer chemotherapy (1) · Volume titrated to clinical status; typical adult bolus 500-1000 mL, then reassess (1) · Vulvovaginal: 150 mg PO single dose; oropharyngeal: 200 mg PO day 1, then 100 mg daily ×14 days; invasive candidiasis: 800 mg load, then 400 mg PO/IV daily; cryptococcal meningitis: 400-800 mg/d (1)

0.25, 0.5 mcg oral capsules; 1 mcg/mL oral solution; 1 mcg/mL IV; 3 mcg/g topical ointment (1) · 0.5% (Carac), 1% (Fluoroplex), 5% (Efudex) topical creams/solutions; 50 mg/mL IV (1) · 0.5, 0.75, 1, 1.5, 2, 4, 6 mg tablets; oral solution; 4, 10, 20, 100 mg/mL IV; intravitreal implant (Ozurdex) (1) · 0.5, 1, 2 mg tablets; 0.25 mg/mL IV (1) · 10, 25, 50, 100 mg tablets; 20 mg/mL IV (1) · 100 mg, 300 mg tablets; IV 500 mg vial (1) · 100 U/mL (NovoLog, Fiasp) vials, pens, cartridges (1) · 125, 250, 500 mg tablets; 125 mg/5 mL, 250 mg/5 mL suspension; 750 mg, 1.5 g IV vials (1) · 2, 4, 8, 16, 32 mg oral tablets; 40, 125, 500, 1000 mg IV vials; Depo-Medrol 20, 40, 80 mg/mL IM depot (1) · 2.5 mg tablets; 10-50 mg/mL injection; pre-filled subcutaneous autoinjectors (Otrexup, Rasuvo); 2.5 mg/mL oral solution (Xatmep) (1) · 2.5, 5, 10, 20 mg tablets; 1 mg/mL oral solution (Epaned); 1.25 mg/mL IV (enalaprilat) (1) · 20 mg, 40 mg delayed-release tablets; 40 mg IV vial; oral suspension 40 mg/packet (1) · 20, 40, 80 mg tablets; 10 mg/mL oral solution; 10 mg/mL IV (1) · 200, 400, 800 mg tablets; 200 mg capsules; 200 mg/5 mL suspension; 500, 1000 mg IV vials; 5% cream and ointment (topical) (1) · 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200, 300 mcg tablets; oral capsule and IV/IM also available (1) · 250 mg, 500 mg, 600 mg tablets; 100, 200 mg/5 mL suspension; 2 g ER suspension (Zmax); 500 mg IV (1) · 250, 500 mg tablets; 750 mg ER; 500 mg/100 mL IV; 0.75-1% topical gel/cream; 0.75% vaginal gel; suppository (1) · 250, 500, 1000 mL IV bags. Composition per liter: Na+ 130 mEq, K+ 4 mEq, Ca2+ 3 mEq, Cl- 109 mEq, lactate 28 mEq (1) · 4 mg, 8 mg, 24 mg tablets; 4 mg, 8 mg orally disintegrating tablets; 4 mg/5 mL oral solution; IV (2 mg/mL) (1) · 5, 10, 20, 100 mg tablets; 10 mg/mL IV (1) · 5, 25, 50 mcg tablets (Cytomel); 10 mcg/mL IV (Triostat) (1) · 50 mg, 75 mg, 100 mg, 150 mg tablets and capsules; delayed-release; suspension; IV (1) · 50, 100, 150, 200 mg tablets; 10, 40 mg/mL oral suspension; 2 mg/mL IV (1) · Auto-injectors 0.15 mg (Jr/pediatric), 0.3 mg (adult); 1 mg/mL (1:1,000) ampules for IM/SC use; 0.1 mg/mL (1:10,000) for IV use; 2.25% racemic nebulizer (1) · IR 30, 60, 90, 120 mg tablets; multiple ER capsules and tablets 60-420 mg; IV 5 mg/mL (1) · IR 40, 80, 120 mg tablets; SR/ER 100-360 mg; IV 2.5 mg/mL (1) · IV 10 mg/mL, 40 mg/mL; inhaled 300 mg/5 mL solution (Tobi, Bethkis); Podhaler dry powder; 0.3% ophthalmic solution and ointment (1) · SL 0.3, 0.4, 0.6 mg tablets; lingual spray 0.4 mg/spray; ER 2.5-9 mg capsules; transdermal patch 0.1-0.8 mg/hr; 2% ointment; 0.4% rectal ointment; 5 mg/mL IV (1) · Tablets 10 mg; injection 15 mg/mL and 30 mg/mL; nasal spray 15.75 mg/spray (Sprix); ophthalmic solution 0.4%, 0.45%, 0.5% (1)

1 g/d (oral); 6 g/d (IV) (1) · 100 mcg/d typical (1) · 120 mg/day (IV/IM); 40 mg/day (oral); '''5-day maximum total combined therapy''' to mitigate the GI bleeding, AKI, and platelet dysfunction risks (1) · 200 mg/d typical practical ceiling (1) · 300 mg/d typical practical limit (toxicity rises sharply above) (1) · 40 mg/d (1) · 40 mg/d typical; up to 240 mg/d for Zollinger-Ellison (1) · 500 mg/d (typical regimen); single 2 g for Zmax; 2 g for select STIs (1) · 600 mg/d typical practical ceiling in heart failure (1) · 800 mg/d (rarely needed) (1) · 800 mg/d (severe invasive disease) (1) · Indication-specific (2) · Indication-specific; ACLS no fixed cumulative ceiling (1) · Indication-specific; high-dose IV regimens for encephalitis or disseminated disease (1) · Indication-specific; titrated to effect (1) · IV: monitored by levels (trough <1 mg/L for extended-interval; <2 mg/L for traditional) (1) · No fixed maximum; titrated to clinical endpoints (1) · No fixed maximum; titrated to TSH target (1) · Rheumatologic ~25 mg/week; oncology indication-specific (1) · Single doses ≤16 mg (FDA 2012 advisory withdrew the 32 mg single IV dose for QT-prolongation risk); 24-32 mg/d divided (1) · Titrated to glucose; no fixed maximum (1) · Titrated; risk of hypercalcemia is the limiting factor (1) · Topical: nightly; systemic: regimen-specific (1) · ~10 mg/d typical (1) · ~200 mg/d for most indications; higher doses for severe infections (1) · ~4 g/d (severe systemic infection) (1) · ~480 mg/d (oral) for cardiovascular indications; higher off-label for cluster (1) · ~480 mg/d (oral); IV per protocol (1)

2-3 hours per dose; full acid suppression after 3-5 days (1) · 30 minutes (IM); 30-60 minutes (oral) (1) · 30 minutes PO; minutes IV (1) · BP effect 1 hour; max at 4-6 hours (1) · Clinical improvement within 24-72 hours (2) · Days for calcium effect; weeks for PTH suppression (1) · Hours (4) · Hours (faster than T4); peak biologic activity 24-48 hours (1) · Hours (systemic); minutes (ophthalmic) (1) · IM: 5-10 minutes; IV: seconds; nebulized: 5-10 minutes (1) · Immediate intravascular expansion (1) · IV pulse: hours; PO: hours; intra-articular: days (1) · IV: 1-3 minutes (SVT termination); PO IR: 30-60 minutes; ER: hours (1) · IV: 3-7 minutes (rate control); PO IR: 30-60 minutes; ER: hours (1) · IV: 5 minutes; PO: 30-60 minutes (1) · IV: 5-20 minutes; PO: 30-60 minutes (1) · PO 1 hour; IV 10 minutes (1) · PO 30-60 minutes; IV minutes (1) · Rheumatologic effect at 4-8 weeks; ectopic resolution over 2-3 weeks (1) · SC: 5-15 minutes (Fiasp 2.5 minutes earlier on average) (1) · Serum urate falls gradually over days to weeks; acute flare prevention requires colchicine cover during initiation (1) · SL/spray: 1-3 minutes; IV: minutes; patch: 30-60 minutes (1) · Symptom relief within 24-48 hours of starting episodic treatment (1) · Topical: inflammation, erythema, crusting at 2 weeks; complete response weeks to months after course (1) · TSH normalization 4-8 weeks; symptomatic improvement weeks to months (1)

12 hours (1) · 12-24 hours (1) · 24 hours (2) · 24+ hours (irreversible enzyme binding) (1) · 24-72 hours (1) · 3-5 hours (1) · 4-12 hours (1) · 4-6 hours (2) · 5-15 minutes (1) · 6-12 hours systemic (1) · 6-8 hours (1) · 8 hours per oral dose (1) · 8-12 hours (2) · Biologic 12-36 hours (intermediate-acting); Depo-Medrol depot weeks (1) · Biologic 36-72 hours (long-acting) (1) · Hours per dose (much shorter biologic effect than ergocalciferol/cholecalciferol because it is the already-active form, not the storage form) (1) · IR: 4-8 hours; ER: 24 hours (1) · IR: 6-8 hours; ER: 24 hours (1) · IV: 1-4 hours; PO: 3-8 hours (1) · IV: ~2 hours; PO: 6-8 hours (1) · N/A (1) · Once-weekly dosing in rheumatology (1) · Roughly 20-30% remains intravascular at 1 hour (1) · SL: 30 minutes; patch: 12-14 hours; IV continuous (1) · Steady-state at 4-6 weeks (1) · Tissue half-life supports once-daily and post-treatment effect (1)

100% (IV) (1) · 40-80% (oral); reduced by food, calcium, iron, PPIs, fiber; take fasting with water'"`UNIQ--ref-00000037-QINU`"' (1) · 60-70% PO at low doses; saturable at high doses (parenteral routes preferred above 15-25 mg/week)'"`UNIQ--ref-000007C9-QINU`"' (1) · >90% (oral; not affected by food or gastric pH — a major practical advantage over itraconazole)'"`UNIQ--ref-00000A48-QINU`"' (1) · High (oral)'"`UNIQ--ref-00001165-QINU`"' (1) · Highly route-dependent: SL bypasses first-pass; oral has extensive first-pass (used only for chronic ER preparations); transdermal predictable'"`UNIQ--ref-00000C10-QINU`"' (1) · IM/SC ~100%; oral negligible (extensive first-pass and gut metabolism — hence the no-oral route)'"`UNIQ--ref-00000E53-QINU`"' (1) · IV/IM ~100%; inhaled: minimal systemic; oral: negligible (not used orally for systemic infection)'"`UNIQ--ref-000010B4-QINU`"' (1) · Topical: minimal systemic absorption (oral systemic 5-FU not used due to poor and variable absorption)'"`UNIQ--ref-000011BF-QINU`"' (1) · ~100% (oral, but oral use is limited to continuation from parenteral)'"`UNIQ--ref-00000021-QINU`"' (1) · ~100% from subcutaneous depot (1) · ~20% (oral; valacyclovir prodrug raises this to ~55%)'"`UNIQ--ref-00000910-QINU`"' (1) · ~20-35% (oral; extensive first-pass via CYP3A4 with R/S enantiomer differences)'"`UNIQ--ref-00000A6C-QINU`"' (1) · ~25-50% (oral; substantial first-pass via NAT2 acetylation, phenotype-dependent)'"`UNIQ--ref-00000688-QINU`"' (1) · ~37% (oral, as axetil prodrug; food modestly improves absorption)'"`UNIQ--ref-00000FFA-QINU`"' (1) · ~37% (oral; food reduces absorption modestly)'"`UNIQ--ref-000003FD-QINU`"' (1) · ~40% (oral; extensive first-pass via CYP3A4)'"`UNIQ--ref-00000643-QINU`"' (1) · ~50% (oral; highly variable, 10-100%, hence the standard 1:2 IV-to-PO conversion)'"`UNIQ--ref-00000223-QINU`"' (1) · ~60% (oral)'"`UNIQ--ref-00000379-QINU`"' (1) · ~60% (oral; food does not affect absorption)'"`UNIQ--ref-00000B85-QINU`"' (1) · ~77% (oral; not affected by food or antacids)'"`UNIQ--ref-0000011E-QINU`"' (1) · ~80% (oral)'"`UNIQ--ref-00000310-QINU`"' (1) · ~80% (oral)'"`UNIQ--ref-00000BEC-QINU`"' (1) · ~80% (oral)'"`UNIQ--ref-00000E2C-QINU`"' (1) · ~80% (oral; predictable absorption — a substantive practical advantage over furosemide whose oral absorption is 10-100% variable)'"`UNIQ--ref-00000B47-QINU`"' (1) · ~80-95% (oral; more reliable than furosemide, comparable to torsemide)'"`UNIQ--ref-00000DE4-QINU`"' (1) · ~80-99% (oral)'"`UNIQ--ref-00000868-QINU`"' (1) · ~95% (oral)'"`UNIQ--ref-0000149E-QINU`"' (1) · ~95% (oral; reduced by dairy, antacids, iron via divalent-cation chelation, though less than for tetracycline itself)'"`UNIQ--ref-0000047E-QINU`"' (1)

Showing below up to 29 results in range #1 to #29.

A

B

Bumetanide

C

D

E

Enalapril

Epinephrine

F

L

M

N

Nitroglycerin

O

Ondansetron

P

Pantoprazole

T

V

Verapamil